Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Universitair Ziekenhuis Brussel
Modality
radiopharmaceutical
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03924466CT.gov Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Salivary Gland Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 68GaNOTA-Anti-HER2 VHH1 (this asset) | Universitair Ziekenhuis Brussel | P2 | CCC · 51 |
| Cetuximab | Fox Chase Cancer Center | P1/2 | B |
| Trastuzumab | Genentech, Inc. | P2 | B |
| Carboplatin | European Organisation for Research and Treatment of Cancer - EORTC | P2 | B |
| Irinotecan | AIDS Malignancy Consortium | P1/2 | B |
| Pembrolizumab | OncoC4, Inc. | P2 | B |
| Pertuzumab | Genentech, Inc. | P2 | CCC |
| Atezolizumab | Genentech, Inc. | P2 | CCC |
| Vismodegib | Genentech, Inc. | P2 | CCC |
+34 more in the Salivary Gland Cancer cohort
Other indications for 68GaNOTA-Anti-HER2 VHH1
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| HER2 Positive Breast Carcinoma | — | P2 | CCC · 52 |
| Malignant Pancreatic Neoplasm | — | P2 | CCC · 51 |
| Uterine Cancer | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 68GaNOTA-Anti-HER2 VHH1 in Salivary Gland Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/68ganota-anti-her2-vhh1-salivary-gland-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →